Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.69 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.54 |
| ▸ | ABAT | P80404 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897071 | 0.87 | XDH (0.81) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| 3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL28213417 | 0.82 | XDH (0.93) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| 3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL346035 | 0.81 | XDH (1.00) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| SCHEMBL17320649 | 0.81 | XDH (0.53) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| 3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL29357099 | 0.81 | XDH (1.00) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| 3,4-Dihydroxy-5-Nitrobenzaldehyde SCHEMBL8731720 | 0.80 | XDH (0.96) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| SCHEMBL3601360 | 0.80 | XDH (0.51) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| SCHEMBL15783651 | 0.80 | XDH (0.71) | XDHALDH5A1ABATERN1 | |
| SCHEMBL14035450 | 0.79 | XDH (0.58) | XDHGPR35ALDH1A1ALDH5A1ABAT | |
| SCHEMBL531545 | 0.79 | XDH (0.69) | XDHGPR35ALDH1A1ALDH5A1ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107954876-B | Preparation method of 3-methyl-4-hydroxy-5-nitrobenzaldehyde | 南通大学 | 2020-05-08 | — | — | CN | claimed |
| CN-107954876-A | The preparation method of 3- methyl -4- hydroxyl -5- nitrobenzaldehydes | 南通大学 | 2018-04-24 | — | — | CN | claimed |
| CN-107954876-B | Preparation method of 3-methyl-4-hydroxy-5-nitrobenzaldehyde | 南通大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-107954876-B | Preparation method of 3-methyl-4-hydroxy-5-nitrobenzaldehyde | 南通大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-107954876-B | Preparation method of 3-methyl-4-hydroxy-5-nitrobenzaldehyde | 南通大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-107954876-A | The preparation method of 3- methyl -4- hydroxyl -5- nitrobenzaldehydes | 南通大学 | 2018-04-24 | — | — | CN | disclosed |
| CN-107954876-A | The preparation method of 3- methyl -4- hydroxyl -5- nitrobenzaldehydes | 南通大学 | 2018-04-24 | — | — | CN | disclosed |
| US-9622988-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-04-18 | — | — | US | disclosed |
| US-9610257-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-04-04 | — | — | US | disclosed |
| US-9585847-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585848-B2 | Small molecule xanthine oxidase inhibitors and methods of use | BAYLOR COLLEGE OF MEDICINE (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| US-7385072-B2 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2008-06-10 | — | — | US | disclosed |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | SCHWARZ PHARMA AG (DE) | 2008-05-01 | — | — | US | disclosed |
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070060767-A1 | Methods for the preparation of Entacapone | SUVEN LIFE SCIENCES (IN) | 2007-03-15 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | XDH 1/4885GPR35 2206/4885ALDH1A1 782/4885 |
| US-20080103191-A1 | ENTACAPONE-DERIVATIVES | ENTPD5, ENTPD3, ENTPD1 | XDH 514/4885GPR35 684/4885ALDH1A1 777/4885 |
| US-20070060767-A1 | Methods for the preparation of Entacapone | OTC, NAAA, GNE | XDH 390/4885GPR35 1281/4885ALDH1A1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.